Age-Related Macular Degeneration: New Paradigms for Treatment and Management of AMD

Abstract EN

Age-related macular degeneration (AMD) is a well-characterized and extensively studied disease.

It is currently considered the leading cause of visual disability among patients over 60 years.

The hallmark of early AMD is the formation of drusen, pigmentary changes at the macula, and mild to moderate vision loss.

There are two forms of AMD: the “dry” and the “wet” form that is less frequent but is responsible for 90% of acute blindness due to AMD.

Risk factors have been associated with AMD progression, and they are taking relevance to understand how AMD develops: (1) advanced age and the exposition to environmental factors inducing high levels of oxidative stress damaging the macula and (2) this damage, which causes inflammation inducing a vicious cycle, altogether causing central vision loss.

There is neither a cure nor treatment to prevent AMD.

However, there are some treatments available for the wet form of AMD.

This article will review some molecular and cellular mechanisms associated with the onset of AMD focusing on feasible treatments for each related factor in the development of this pathology such as vascular endothelial growth factor, oxidative stress, failure of the clearance of proteins and organelles, and glial cell dysfunction in AMD.